Prediction Models for Voriconazole Pharmacokinetics Based on Pharmacogenetics: An Exploratory Study in Spanish population

Abstract Individualization of the therapeutic strategy for the oral antifungal voriconazole (VCZ) is extremely important for treatment optimization. To date, regulatory agencies include CYP2C19 as the only major pharmacogenetics (PGx) biomarker in their dosing guidelines; however, the effect of other genes might be important for VCZ dosing prediction. We developed an exploratory PGx study to identify new biomarkers related to VCZ pharmacokinetics (PK). We first designed a “Clinical Practice VCZ-AUC prediction model” based on CYP2C19 to be used as a reference model in this study. We then designed a multifactorial polygenic prediction